Technical Analysis for EGRX - Eagle Pharmaceuticals, Inc.
|Grade||Last Price||% Change||Price Change|
EGRX closed down 0.11 percent on Friday, February 16, 2018, on 89 percent of normal volume. The price action carved out a bearish shooting star candlestick pattern. That may indicate a downside reversal. Look for price to trade beneath the low of the shooting star for confirmation. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a pullback should not be unexpected.
|Weak or Absent||Up||Up||Up|
|See historical EGRX trend table...|
|Date||Alert Name||Type||% Chg|
|Feb 16||Shooting Star Candlestick||Bearish||0.00%|
|Feb 16||Lizard Bearish||Bearish Day Trade Setup||0.00%|
|Feb 16||Doji - Bearish?||Reversal||0.00%|
|Feb 16||Upper Bollinger Band Walk||Strength||0.00%|
|Feb 16||Wide Bands||Range Expansion||0.00%|
|Feb 16||Above Upper BB||Strength||0.00%|
|Feb 16||Overbought Stochastic||Strength||0.00%|
|Feb 15||Upside 200 DMA Break||Bullish||-0.11%|
|Feb 15||Expansion Breakout||Bullish Swing Setup||-0.11%|
|Feb 15||Stochastic Reached Overbought||Strength||-0.11%|
Get a Trading Sidekick!
Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicatorsBasic chart:
Eagle Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing injectable products primarily in the critical care and oncology areas in the United States. The company markets EP-1101 (argatroban) to treat heparin-induced thrombocytopenia. It develops EP-3101, a bendamustine ready to dilute (RTD) liquid and EP-3102, a bendamustine short infusion time RTD liquid for the treatment of chronic lymphocytic leukemia and non-Hodgkin's lymphoma; Ryanodex, a dantrolene to treat malignant hyperthermia; and EP-4104, a dantrolene that has completed a Phase I clinical study for the treatment of exertional heat stroke. The company also develops EP-5101 (pemetrexed) as RTD liquid, which is in pre-clinical formulation and toxicology studies to treat lung cancer; EP-6101, a bivalirudin RTU liquid formulation for the treatment of percutaneous transluminal angioplasty; and EP-2101 (topotecan) to treat ovarian, cervical, and small-cell lung cancers. Eagle Pharmaceuticals, Inc. was founded in 2007 and is based in Woodcliff Lake, New Jersey.
|Indicator||Bull Case||Neutral / Hold||Bear Case|
|Oversold / Overbought|
|Summary:||Counts: 3 bullish, 0 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.|
See more EGRX news...
|52 Week High||97.15|
|52 Week Low||45.05|
|200-Day Moving Average||62.6094|
|50-Day Moving Average||58.5164|
|20-Day Moving Average||59.979|
|10-Day Moving Average||59.95|
|Average True Range||2.7586|
|Chandelier Exit (Long, 3 ATRs )||57.7742|
|Chandelier Exit (Short, 3 ATRs )||62.0458|
|Upper Bollinger Band||64.347|
|Lower Bollinger Band||55.611|
|Percent B (%b)||1.05|
|MACD Signal Line||0.4572|
|Market Cap||982.64 Million|
|Num Shares||15.2 Million|
|Price-to-Earnings (P/E) Ratio||10.87|
|Pivot Point Level||Traditional / Classic||Fibonacci||Demark||Woodie||Camarilla|
|Resistance 4 (R4)||67.23|
|Resistance 3 (R3)||67.38||66.71||66.82|
|Resistance 2 (R2)||66.71||66.09||66.64||66.68|
|Resistance 1 (R1)||65.75||65.71||66.23||65.60||66.55|
|Support 1 (S1)||64.12||64.46||64.60||63.97||63.01|
|Support 2 (S2)||63.45||64.08||63.38||62.88|
|Support 3 (S3)||62.49||63.45||62.74|
|Support 4 (S4)||62.34|